GlaxoSmithKline PLC (GSK.L)
BRUSSELS, Aug 19 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
BRUSSELS, Aug 21 - The European Commission cleared on Friday U.S. drugmaker Perrigo's acquisition of certain assets from Britain's GSK.
ZURICH - Novartis has agreed to buy all remaining rights to Ofatumumab from Britain's GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker's stable of multiple sclerosis (MS) treatments.
* Will pay royalties of up to 12 pct on future net sales (Adds comment from head of Novartis Pharmaceuticals, detail)
ZURICH, Aug 21 - Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
* GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties
BRUSSELS, Aug 18 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
LONDON, Aug 13 - GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.
Aug 12 - Drugmaker GlaxoSmithKline temporarily closed a North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire's disease.
- Drugmaker GlaxoSmithKline closed its North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire's disease, a company spokeswoman said.
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (GSK). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of GLAXOSMITHKLINE PLC -ADR including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider : Jefferson Research
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.